Medical Oncology

, Volume 26, Issue 1, pp 45–48 | Cite as

Rituximab-induced acute thrombocytopenia: a case report and review of the literature

  • Jun Ho Yi
  • Seok Jin Kim
  • Hee Kyung Ahn
  • Su Jin Lee
  • Myung Hee Chang
  • Won Seog Kim
Original Paper

Abstract

Rituximab is a chimeric monoclonal antibody directed against the phosphoprotein CD20. Because of its efficacy and acceptable toxicity profile, rituximab is now commonly used for the treatment of CD20-positive B-cell malignancies, including B-cell non-Hodgkin’s lymphoma. However, rituximab-induced acute thrombocytopenia is an extremely rare side effect. We report a case of acute thrombocytopenia occurring immediately after rituximab infusion in a mantle cell lymphoma patient with bone marrow involvement and massive splenomegaly. Although the mechanism of thrombocytopenia is still unclear, it is possible that tumor burden, bone marrow involvement, the presence of infusion-related symptoms, and mantle cell histology are related to this rare complication of rituximab therapy. Hence, rituximab should be used with caution in patients who have these factors, and clinicians must be aware of this rare, but serious, side effect.

Keywords

Thrombocytopenia Rituximab Mantle cell lymphoma 

References

  1. 1.
    Riley JK, Sliwkowski MX. CD20: a gene in search of a function. Semin Oncol. 2000;27:17–24.PubMedGoogle Scholar
  2. 2.
    Cerny T, et al. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(Suppl 2):S3–10.PubMedGoogle Scholar
  3. 3.
    Kami M, et al. Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J. 2003;4:159–62. doi: 10.1038/sj.thj.6200243.PubMedCrossRefGoogle Scholar
  4. 4.
    Chaiwatanatorn K, et al. Delayed-onset neutropenia associated with rituximab therapy. Br J Haematol. 2003;121:913–8. doi: 10.1046/j.1365-2141.2003.04385.x.PubMedCrossRefGoogle Scholar
  5. 5.
    Rigamonti C, et al. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion. Leukemia. 2001;15:186–7. doi: 10.1038/sj.leu.2401987.PubMedCrossRefGoogle Scholar
  6. 6.
    Shah C, Grethlein SJ. Case report of rituximab-induced thrombocytopenia. Am J Hematol. 2004;75:263. doi: 10.1002/ajh.20028.PubMedCrossRefGoogle Scholar
  7. 7.
    Otrock ZK, et al. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica. 2005;90(Suppl):e66–7.Google Scholar
  8. 8.
    Pamuk GE, et al. Rituximab-induced acute thrombocytopenia in a patient with prolymphocytic leukemia. Am J Hematol. 2005;78:81. doi: 10.1002/ajh.20218.PubMedCrossRefGoogle Scholar
  9. 9.
    Thachil J, Mukherje K, Woodcock B. Rituximab-induced haemorrhagic thrombocytopenia in a patient with hairy cell leukaemia. Br J Haematol. 2006;135:273–4. doi: 10.1111/j.1365-2141.2006.06299.x.PubMedCrossRefGoogle Scholar
  10. 10.
    Rosado M, Chao H, Rose M. Severe acute thrombocytopenia following rituximab therapy. Leukemia & Lymphoma.. 2007;48:2239–40. doi: 10.1080/10428190701625099.CrossRefGoogle Scholar
  11. 11.
    Giles FJ, et al. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol. 2003;123:850–7. doi: 10.1046/j.1365-2141.2003.04683.x.PubMedCrossRefGoogle Scholar
  12. 12.
    Huh YO, et al. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001;116:437–43. doi: 10.1309/438 N-E0FH-A5PR-XCAC.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc. 2008

Authors and Affiliations

  • Jun Ho Yi
    • 1
  • Seok Jin Kim
    • 1
  • Hee Kyung Ahn
    • 1
  • Su Jin Lee
    • 1
  • Myung Hee Chang
    • 1
  • Won Seog Kim
    • 1
  1. 1.Division of Hematology and Oncology, Department of Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineGangnam-GuSouth Korea

Personalised recommendations